|
gptkbp:instanceOf
|
gptkb:drug
gptkb:phenothiazine_derivative
|
|
gptkbp:administeredBy
|
palliative care
end-of-life care
|
|
gptkbp:ATCCode
|
N05AA02
|
|
gptkbp:availableOn
|
gptkb:tablet
injectable solution
|
|
gptkbp:brand
|
gptkb:Nozinan
|
|
gptkbp:CASNumber
|
60-04-4
|
|
gptkbp:category
|
gptkb:analgesic
gptkb:antipsychotic_medication
gptkb:antiemetic
|
|
gptkbp:chemicalFormula
|
C18H24N2OS
|
|
gptkbp:contraindication
|
bone marrow depression
severe CNS depression
hypersensitivity to phenothiazines
|
|
gptkbp:discoveredBy
|
gptkb:Rhodia
|
|
gptkbp:discoveredIn
|
1950s
|
|
gptkbp:eliminationHalfLife
|
15-30 hours
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:antihistamine
gptkb:dopamine_receptor_antagonist
anticholinergic
alpha-adrenergic blocker
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
hypotension
sedation
extrapyramidal symptoms
anticholinergic effects
|
|
gptkbp:synonym
|
levomepromazine
|
|
gptkbp:usedFor
|
nausea
schizophrenia
pain management
agitation
|
|
gptkbp:bfsParent
|
gptkb:Levomepromazine
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
methotrimeprazine
|